PDT Partners’s Co-Diagnostics CODX Stock Holding History

PDT Partners’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-689	Closed	-$201K	–	891
2021 Q3	$201K	Buy	+689	New	+$201K	0.01%	692

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

ARC

Advisor Resource Council Dallas, Texas $355M AUM 30.05% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PDT Partners's CODX Position: Q4 2021 in Review

PDT Partners sold out of Co-Diagnostics (CODX) in Q4 2021, closing a stake of 689 shares — an estimated $201K sold.

PDT Partners first reported a position in CODX in Q3 2021 and held it in 1 quarter. The position peaked at $201K in Q3 2021. 77 funds tracked by Wall St. Rank hold CODX as of Q4 2021.

PDT Partners reported no remaining Co-Diagnostics position as of Q4 2021 after selling out during the quarter.
PDT Partners sold 689 Co-Diagnostics shares in Q4 2021, an estimated $201K.
PDT Partners first reported a position in Co-Diagnostics in Q3 2021 and held it in 1 quarter.
PDT Partners's Co-Diagnostics position peaked at $201K in Q3 2021.
77 funds tracked by Wall St. Rank held Co-Diagnostics as of Q4 2021.

Based on PDT Partners's 13F filing for Q4 2021, filed 14 Feb 2022.